ReviewBritish journal of cancer2004
Negative regulation of ErbB family receptor tyrosine kinases.
Review in British journal of cancer, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 54 citations in OpenAlex.
- An AI-derived peptide PCa2 suppresses pancreatic cancer growth via modulation of the ErbB/PI3K/AKT/mTOR/MYC signaling axis.Cell communication and signaling : CCS · 2026Article
- KITENIN promotes aerobic glycolysis through PKM2 induction by upregulating the c-Myc/hnRNPs axis in colorectal cancer.Cell & bioscience · 2023Article
- Structural arrangement of the active back-to-back dimer in N-glycosylated ErbB receptors is regulated by heterodimerization.Molecular biology research communications · 2023Article
- Article
- Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab.Cancer management and research · 2016Review
- Article
- Enteropathogenic Escherichia coli dynamically regulates EGFR signaling in intestinal epithelial cells.American journal of physiology. Gastrointestinal and liver physiology · 2014Article
- Epidermal growth factor receptor down-regulation triggers human myoblast differentiation.PloS one · 2013Article
- ErbB signaling in cardiac development and disease.Seminars in cell & developmental biology · 2010Review
- miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2009Article
- The ubiquitin ligase Nedd4 mediates oxidized low-density lipoprotein-induced downregulation of insulin-like growth factor-1 receptor.American journal of physiology. Heart and circulatory physiology · 2008Article
- Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs.Cancer letters · 2008Article
- The ERBB3 receptor in cancer and cancer gene therapy.Cancer gene therapy · 2008Review
- Neuregulin-1: a potential endogenous protector in perinatal brain white matter damage.Neonatology · 2008Review
- Arsenite and insulin exhibit opposing effects on epidermal growth factor receptor and keratinocyte proliferative potential.Toxicology and applied pharmacology · 2007Article
- Neuregulin-induced ErbB3 downregulation is mediated by a protein stability cascade involving the E3 ubiquitin ligase Nrdp1.Molecular and cellular biology · 2007Article
- Involvement of alpha6beta4 integrin in the mechanisms that regulate breast cancer progression.Breast cancer research : BCR · 2007Article
- Transforming growth factor alpha acts as a gliatrophin for mouse and human astrocytes.Oncogene · 2006Article
- Review
- ErbB receptor negative regulatory mechanisms: implications in cancer.Journal of mammary gland biology and neoplasia · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Receptors of the EGF receptor or ErbB family of growth factor receptor tyrosine kinases are frequently overexpressed in a variety of solid tumours, and the aberrant activation of their tyrosine kinase activities is thought to contribute to tumour growth and progression. Much effort has been put into developing inhibitors of ErbB receptors, and both antibody and small-molecule approaches have exhibited clinical success. Recently, a number of endogenous negative regulatory proteins have been identified that suppress the signalling activity of ErbB receptors in cells. These include intracellular RING finger E3 ubiquitin ligases such as cbl and Nrdp1 that mediate ErbB receptor degradation, and may include a wide variety of secreted and transmembrane proteins that suppress receptor activation by growth factor ligands. It will be of interest to determine the extent to which tumour cells suppress these pathways to promote their progression, and whether restoration of endogenous receptor-negative regulatory pathways may be exploited for therapeutic benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.